Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

RFA-DK-25-012: Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)

Closed Closed October 24, 2024 Opportunity RFA-DK-25-012

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.

National Institutes of Health offered grants of up to $5.5 million to small businesses. Applications closed on October 24, 2024.

From the official notice on Grants.gov, last changed June 5, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under RFA-DK-25-012 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-25-012 in the NIH Guide.

Key dates

PostedJune 5, 2024
DeadlineOctober 24, 2024
Archived by Grants.govNovember 29, 2024

Who can apply

This opportunity was open to small businesses.

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See full Notice of Funding Opportunity for additional details on eligibility. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

More grants for small businesses.

Is this a realistic fit?

What the grant funds

This Notice of Funding Opportunity (NOFO) is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement to the University of Pennsylvania to continue the mission of the existing Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D). This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; immunology and autoimmunity; collection, processing and multimodal analysis of human pancreatic tissues and immune compartments; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues and immune cells from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through the existing PANC DB open-access resource database. HPAP-T1D is a component of the Human Islet Research Network or HIRN. HIRN was created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

Category: Food and Nutrition, Health.

Funded under RFA-DK-25-012 so far

NIH funded 1 project under RFA-DK-25-012 in fiscal 2025 to 2026, at 1 institution. The median yearly award was $8.9 million.

Recently funded projects
ProjectInstitutionFiscal yearAward
Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1D U01University of Pennsylvania2026$8.9 million

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before

From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Regents of the University of MichiganMichigan273$345 million
The Trustees of the University of PennsylvaniaPennsylvania187$272 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania209$238 million
The Washington UniversityMissouri187$227 million
The Regents of the University of California, San FranciscoCalifornia176$208 million

Top states: California ($1.2 billion), Massachusetts ($932 million), New York ($798 million), Pennsylvania ($762 million), Texas ($482 million).

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is RFA-DK-25-012 still open?

No. It closed on October 24, 2024.

Who can apply for Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)?

Closed October 24, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

How much funding is available?

Awards of up to $5.5 million each.

Who has been funded under RFA-DK-25-012?

NIH RePORTER lists 1 project funded under RFA-DK-25-012 in fiscal 2025 to 2026, at 1 institution.

Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.

Similar open grants